Skip to main content
logo
Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.2470
+0.0070 (2.92%)
Sep 22, 2026, 3:17 PM EST

Elite Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
141.01148.8784.0456.6334.1632.26
Revenue Growth
33.72%77.13%48.42%65.79%5.87%27.11%
Gross Profit
61.3175.0240.0926.3616.5914.8
Operating Income
35.7949.9621.210.793.975.07
Net Income
56.6744.87-4.3120.113.568.9
Earnings Per Share
0.040.03-0.000.020.000.01
EPS Growth
---537.54%-57.99%81.05%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
38.9429.811.327.117.838.54
Total Debt
5.575.8210.9111.743.892.78
Net Cash (Debt)
33.3723.980.4-4.633.945.75
Net Cash Growth
121.52%5888.11%---31.44%606.63%
Net Cash Per Share
0.030.020.00-0.000.000.01

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
19.0423.757.46-3.243.346.51
Capital Expenditures
-1.52-0.93-1.63-0.81-5.74-0.5
Free Cash Flow
17.5322.825.83-4.04-2.46.01
Free Cash Flow Growth
-2.76%291.43%---109.85%

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
43.48%50.40%47.70%46.55%48.58%45.86%
Operating Margin
25.38%33.56%25.23%19.05%11.62%15.72%
Pretax Margin
46.16%38.16%-0.06%0.82%11.67%22.20%
Profit Margin
40.19%30.14%-5.13%35.51%10.43%27.58%
FCF Margin
12.43%15.33%6.94%-7.14%-7.02%18.63%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
5.628.64-7.818.263.97
P/FCF Ratio
15.1816.9979.70--5.88
PS Ratio
1.892.615.532.770.861.10